Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.07
(
0.76%
)
US TECH 100
28,844.80
(
0.90%
)
Dow Jones
50,072.11
(
0.76%
)
Brent Oil
103.71
(
0.01%
)
Bitcoin
81,827.29
(
3.21%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: cjgaddy post# 246188

Sunday, 12/20/2015 11:37:00 AM

Sunday, December 20, 2015 11:37:00 AM

Post# of 347009
Great post CJ. I agree 100% and I got a call this morning from a very recent investor in PPHM asking about that AstraZeneca partnership and this new investor was actually reading some of the misinformation that was posted. Your post cleared it up perfectly!

Thanks.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote